Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.780
+0.220 (6.18%)
At close: Sep 5, 2025, 4:00 PM
3.730
-0.050 (-1.32%)
After-hours: Sep 5, 2025, 7:41 PM EDT
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $20.00K, down -95.11% year-over-year. In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%.
Revenue (ttm)
$20.00K
Revenue Growth
-95.11%
P/S Ratio
16,680.62
Revenue / Employee
$339
Employees
59
Market Cap
333.61M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ALT News
- 1 day ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - PRNewsWire
- 10 days ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - GlobeNewsWire
- 11 days ago - Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade) - Seeking Alpha
- 12 days ago - Altimmune to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 19 days ago - Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) - GlobeNewsWire
- 20 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT - PRNewsWire
- 23 days ago - Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT) - PRNewsWire
- 25 days ago - Altimmune, Inc. (ALT) Q2 2025 Earnings Call Transcript - Seeking Alpha